Weak Free Cash Flow GenerationA steep drop in free cash flow (-35.2%) and low FCF-to-income (0.18) signal weak cash conversion. Over months, this constrains capex, working capital funding, dividends, and forces reliance on external financing, limiting strategic flexibility despite a strong balance sheet.
Top-line PressureYear‑over‑year revenue decline indicates structural demand or volume challenges in core segments. Persistent top-line weakness limits operating leverage, caps long-term growth in breeding and health segments, and makes sustained margin gains more dependent on efficiency than scale.
Modest Returns On CapitalA middling ROE (~7.9%) implies limited ability to convert capital into high returns. Over the medium term, modest capital returns can constrain reinvestment payoff and shareholder value creation, making it harder to outpace competitors without material earnings or efficiency improvements.